SNG vs. ONC, SBTX, BVX, ROQ, NSCI, BSFA, IMM, SAR, VAL, and GENF
Should you be buying Synairgen stock or one of its competitors? The main competitors of Synairgen include Oncimmune (ONC), SkinBioTherapeutics (SBTX), BiVictriX Therapeutics (BVX), Roquefort Therapeutics (ROQ), NetScientific (NSCI), BSF Enterprise (BSFA), ImmuPharma (IMM), Sareum (SAR), ValiRx (VAL), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.
Synairgen (LON:SNG) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
In the previous week, Oncimmune had 1 more articles in the media than Synairgen. MarketBeat recorded 1 mentions for Oncimmune and 0 mentions for Synairgen. Oncimmune's average media sentiment score of 0.67 beat Synairgen's score of 0.00 indicating that Oncimmune is being referred to more favorably in the news media.
Oncimmune has a net margin of 356.25% compared to Synairgen's net margin of 0.00%. Synairgen's return on equity of -48.86% beat Oncimmune's return on equity.
28.8% of Synairgen shares are owned by institutional investors. Comparatively, 35.5% of Oncimmune shares are owned by institutional investors. 3.3% of Synairgen shares are owned by insiders. Comparatively, 28.8% of Oncimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Synairgen has a beta of -2.23, meaning that its stock price is 323% less volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Oncimmune has higher revenue and earnings than Synairgen. Oncimmune is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.
Synairgen received 85 more outperform votes than Oncimmune when rated by MarketBeat users. However, 59.13% of users gave Oncimmune an outperform vote while only 56.46% of users gave Synairgen an outperform vote.
Summary
Oncimmune beats Synairgen on 10 of the 15 factors compared between the two stocks.
Get Synairgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Synairgen Competitors List
Related Companies and Tools